Fate Therapeutics Inc
Veridion Score
Composite trend over time
Why is FATE moving today?
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for FATE.
FATE insider activity
Fate Therapeutics Inc
3 insiders bought in the last 90 days
Net buying: $148K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | 2026-05-20 | TAHL CINDY | Insider | sell | $1.88 | 25,590 | 628,155 | $48K | SEC Form 4 |
| 2026-05-21 | 2026-05-20 | Valamehr Bahram | Insider | sell | $1.88 | 28,946 | 635,762 | $54K | SEC Form 4 |
| 2026-05-07 | 2026-05-06 | TAHL CINDY | Insider | buy | $1.05 | 44,444 | 653,745 | $47K | SEC Form 4 |
| 2026-05-07 | 2026-05-06 | TAHL CINDY | Insider | buy | $1.32 | 122,220 | 609,301 | $161K | SEC Form 4 |
| 2026-05-06 | 2026-05-05 | EPSTEIN ROBERT S | Insider | buy | $1.69 | 25,000 | 36,331 | $42K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 5 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moFATE contract awards, year to date.
Public federal awards linked to this ticker.
FATE lobbying filings, year to date.
Registered lobbying filings matched to Fate Therapeutics Inc.